

SSG Newsletter, February 2023

Dear SSG-member!

We are glad to inform you that we have a new member in the board, Stine Kirchhoff-Christensen from Copenhagen, Denmark. Stine will replace Lotta Våde from Oslo. We would all like to thank Lotta for her great support and all the work that she has done for SSG during the years!

The SSG board would like to inform you about some new initiatives that we will launch during the coming year. Kathrin Pulverer will take on the role as Scientific Advisor and will summarize important news and research updates in the sarcoma field. She will get regular information from each working group leader and the updates will be published in the newsletter. We would also be happy to receive proposals directly from all members. We plan to send out the newsletters three times yearly.

The rEECUr study will continue with three arms for recurrent Ewing sarcoma. One arm where patients will get treatment with high-dose Ifosfamide, another arm with Carboplatin-Etoposide and the experimental arm will test a combination with Ifosfamide and Lenvatinib. We are now waiting for approval from the UK authorities. We will investigate the possibilities for Sweden to join.

The preparations for the 41st SSG congress in Gothenburg in May 2024 have started with a very engaged local committee! The meeting will focus on MultiDisciplinary Conference (MDC) work and treatment of pelvic tumors, especially chordoma and chondrosarcoma. We have an interesting list of proposed speakers that we will try to invite. The meeting will take place in May 22-24, 2024, at Elite Park Avenue at Kungssportsavenyn in central Gothenburg and there will also be a nice social program. We look forward to seeing you all there and updates on our website, www.ssg-org.net, from the program committee will follow continuously.

We gratefully receive proposals about speakers and activities from each working group. We also look forward to receiving a lot of abstracts especially from the PhD-students! This was very much appreciated at our last meeting in Tampere, and we will continue to encourage our young students to come and present their work.

At Karolinska University Hospital we will start a phase 1 study in March where patients with metastasizing or locally advanced soft tissue sarcoma can be included. It is a study with a MDM2 antagonist. Thus, the patients must have an MDM2 amplified tumor. Patients with a p53 mutation cannot be included.

If you want further information, you are welcome to contact Christina Linder-Stragliotto, christina.linder-stragliotto@regionstockholm.se at the sarcoma unit or the phase 1 study unit at Karolinska University Hospital.

The SSG board is also planning to continue to work with the suggestion from the previous board to implement a travelling fellowship for young health care professionals to get possibility to visit one of the sarcoma centers in the membership countries. We hope that this will spread ideas and enhance knowledge about treatment of sarcoma and create new personal contacts between centers. We are now working on the practicalities to make this possible and will come back with details about eligibility and how to apply.

The 2023 Working Group Meeting will take place in Malmö on December 4-5. Please, feel free to come up with ideas about what you want to discuss at the meeting.

On behalf of the board,

Christina Linder Stragliotto and Eva-Mari Olofsson